Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,210
  • Shares Outstanding, K 114,604
  • Annual Sales, $ 13,630 K
  • Annual Income, $ -186,260 K
  • EBIT $ -196 M
  • EBITDA $ -186 M
  • 60-Month Beta 2.41
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book 0.40

Options Overview Details

View History
  • Implied Volatility 326.60% ( +8.09%)
  • Historical Volatility 121.80%
  • IV Percentile 93%
  • IV Rank 59.44%
  • IV High 541.64% on 12/12/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 52
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 6,667
  • Open Int (30-Day) 5,426

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.39
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.45
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +17.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6611 +67.90%
on 04/04/25
1.1800 -5.93%
on 04/16/25
+0.1437 (+14.87%)
since 03/17/25
3-Month
0.6611 +67.90%
on 04/04/25
1.8100 -38.67%
on 02/19/25
-0.1600 (-12.60%)
since 01/17/25
52-Week
0.6611 +67.90%
on 04/04/25
5.9200 -81.25%
on 07/26/24
-4.1600 (-78.94%)
since 04/17/24

Most Recent Stories

More News
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...

KRYS : 168.57 (+2.35%)
JAZZ : 102.78 (+1.21%)
ADMA : 21.31 (+0.38%)
FATE : 1.1100 (+5.71%)
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.

VTI : 258.75 (+0.21%)
FATE : 1.1100 (+5.71%)
IWM : 186.48 (+0.82%)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

FATE : 1.1100 (+5.71%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.1100 (+5.71%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.4500 (+3.57%)
ONCY : 0.5610 (-1.23%)
TARA : 3.90 (-2.50%)
YMAB : 4.69 (+3.30%)
FATE : 1.1100 (+5.71%)
ONC.TO : 0.77 (-1.28%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 1.1100 (+5.71%)
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

FATE : 1.1100 (+5.71%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.1100 (+5.71%)
Fate Therapeutics to Present at Upcoming Investor Conferences

FATE : 1.1100 (+5.71%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 1.1100 (+5.71%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 1.3251
2nd Resistance Point 1.2475
1st Resistance Point 1.1788
Last Price 1.1100
1st Support Level 1.0325
2nd Support Level 0.9549
3rd Support Level 0.8862

See More

52-Week High 5.9200
Fibonacci 61.8% 3.9111
Fibonacci 50% 3.2905
Fibonacci 38.2% 2.6700
Last Price 1.1100
52-Week Low 0.6611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar